what's a crypto Top searches

Navigation warning! Sea shooting test in the southern Yellow Sea, according to the website of China Maritime Safety Administration, Lianyungang Maritime Safety Administration issued a navigation warning. From 8: 00 to 14: 00 on December 11, some sea areas in the southern Yellow Sea were fired with live ammunition, and it was forbidden to enter.Everbright Securities: It is expected that the auto market will usher in the year-end impulse market in December. Everbright Securities reported on December 10 that with the introduction of preferential policies for car purchases by various auto companies at the end of the year and the continuous promotion of trade-in by local governments, it is expected that the auto market will usher in the year-end impulse market in December. Recommend the big white horse bibcock of each subdivision track, and pay attention to the sales of new models in 2025E to achieve high flexibility. 2025E intelligence will continue to become a competitive highland in the industry, paying attention to intelligent theme investment opportunities.GM will withdraw from the driverless taxi business, and the Cruise self-driving car division of GM will withdraw from the driverless taxi business. According to a statement on Tuesday, Cruise and GM's technical team will be combined to focus on developing autonomous driving and advanced driver safety technology for GM's future sales models. GM said that it will no longer provide funds for the development of self-driving taxis "considering the large amount of time and resources needed to expand its business scale and the increasingly fierce competition in the self-driving taxi market". The company said that giving up the development of self-driving taxis will save it more than $1 billion in annual costs.

Expert: Central enterprises will continue to recruit in A-shares. On the evening of December 9, Huada Jiutian, a domestic EDA leader, announced that China Electronic Information Industry Group Co., Ltd. will become the actual controller of the company. So far, the number of A-share listed companies "incorporated" by central enterprises reached 10 in 2024. The end of 2024 is an important node for central enterprises to optimize the layout of listed platforms. The Work Plan for Improving the Quality of Listed Companies Controlled by Central Enterprises previously issued by the State-owned Assets Supervision and Administration Commission of the State Council made it clear that the adjustment and revitalization of the listing platform should be basically completed by the end of 2024, and it is supported to revitalize through absorption and merger, asset restructuring and cross-market operation, or to withdraw through free transfer and equity transfer, so as to further focus on the main business and advantageous areas. Looking forward to the next layout rhythm of central enterprises in the capital market, many experts interviewed by reporters believe that the pace of "recruiting" of central enterprises in A shares will continue. In the coming period, the cases of central enterprises strengthening their main business through capital operation and giving play to their strategic support and industrial leading functions will be on the rise. (shanghai securities news)The negotiation between Myriad and United Health Insurance may be extended to the beginning of 2025, and the negotiation between Myriad Genetics and UnitedHealthcare on the genetic test of Myriad may continue until the beginning of 2025. Myriad reiterated its estimate of the financial impact of the United Health Insurance Company's updated medical policy in 2024.Huatai Securities: The policy overweight boosts consumption and is optimistic about the four main lines. Huatai Securities Research Report said that with the continuous efforts of promoting consumption policies, the large consumer sector ushered in the configuration window period and continued to be optimistic about the basic orientation and valuation repair of the consumer sector. It is suggested to pay attention to four main investment lines: 1) the rise of domestic products: the strength and brand power of domestic products in beauty care, home appliances, pets, textiles and clothing are constantly improving, occupying consumers' minds against the trend, and domestic products continue to lead; 2) Emotional consumption: the products on the supply side are continuously iterated, and the goods/services are built as a medium to convey emotional value, and the consumption on the demand side is superimposed to promote the continuous expansion of the tide play /IP economy; 3) New cost performance: The consumption concept of residents is becoming more and more rational, and the quality-price ratio has become the core of consumption decision-making. The new cost performance consumption focusing on "good but not expensive" is expected to continue to grow rapidly; 4) Consumption going to sea: Going to sea has become a necessary topic for consumer enterprises. Under the two-way catalysis of supply and demand, China enterprises are actively participating in global market competition and paying attention to brand/culture/service going to sea.

Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.Ministry of Finance of Korea: Korea's financial market is still facing uncertainty.On December 10th, 36 stocks hit record highs mainly in transportation equipment, mechanical equipment and other industries. According to statistics, on December 10th, a total of 36 stocks hit record highs, mainly in transportation equipment, mechanical equipment and other industries, including Cyrus, Tuosida, Keli Sensing, Straight Flush, Focus Technology and so on.